Some products of Shanghai RAAS cancel the limited payment scope of medical insurance


According to the official website of the State Medical Insurance Bureau, in order to further improve the level of medication security for insured personnel,In accordance with the Interim Measures for the Administration of Drugs Used in Basic Medical Insurance and the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs in 2023According to the requirements of the Work Program for Catalogue Adjustment,The State Medical Insurance Bureau and the Ministry of Human Resources and Social Security have adjusted and formulated the National Basic Medical Insurance, Industrial Injury Insurance and Maternity InsuranceThe Drug Catalogue (2023) has been formally implemented since January 1, 2024.

This catalogue included Human Albumin, IVIG (Human Immunoglobulin for Intravenous Injection), Human Fibrinogen, Human Prothrombin Complex, Human Coagulation Factor VIII, Human Coagulation Factor IX, Human Immunoglobulin, Human Tetanus Immunoglobulin, Human Rabies Immunoglobulin and Recombinant Human Coagulation Factor VIIa, Recombinant Coagulation Factor VIII, and Recombinant Coagulation Factor IX.

Two widely used blood products of coagulation factors: Human Fibrinogen and Human Prothrombin Complex; the restriction on medical insurance payment has been cancelled. The payment limit for Human Prothrombin Complex has been removed for "limited surgery bleeding and bleeding caused by liver disease, hemophilia B and or hemophilia patients with coagulation factor VIII inhibitors"; the payment limit for Human Fibrinogen has been removed for "limited active bleeding caused by hypofibrinogenemia".